Disclaimer: This site analyses public FDA records. It is not medical advice. If you feel unwell, contact a healthcare professional immediately.
Supplement Safety Checker
Notice: Official Public Record

Casmara Cosmetics, S.A. FDA Warning (2018)

Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on February 12, 2018

MODERATE SEVERITY Center for Drug Evaluation and Research 2018
Disclaimer: This report is an analysis of a public FDA warning letter. It is not medical advice. If you have consumed these products and feel unwell, contact a healthcare professional immediately.

Executive Summary

The FDA issued a warning letter to Casmara Cosmetics, S.A. on February 12, 2018 citing regulatory violations. The letter was issued by Center for Drug Evaluation and Research.

Regulatory Violations

Detailed Analysis

False Claims and Regulatory Violations

The FDA identified regulatory violations in Casmara Cosmetics, S.A.'s operations or product claims.

Potential Health Risks

Your procedures to ensure that you test all lots of(b)(4). Provide a current risk assessment of all OTC drug products that contain(b)(4)intended for the U.S. market still within expiry. Provide the results of the testing of retain samples of these lots for(b)(4)and(b)(4).

A current risk assessment of the OTC drug products intended for the U.S. market still within expiry that are not supported by adequate stability testing.

Regulatory Context

Timelines for testing all in-date drug products intended for the U.S., for identity and strength of active ingredients and all other appropriate quality attributes, including total count and objectionable microorganisms. If you find that you released any batch for which release test results were found to be out-of-specification, indicate the corrective actions you will take, such as customer notifications and product recalls.

Timelines for process performance qualification for each of your drug products. For any drugs distributed to the U.S. before validation activities are completed, provide an interim plan to ensure the quality of drug products that you continue to manufacture and distribute. Provide a detailed summary of your approach for routinely monitoring intra-batch and inter-batch variation.

Key Entities Identified

Casmara Cosmetics S.A. FDA Warning Letter

Frequently Asked Questions

What did the FDA find wrong with Casmara Cosmetics, S.A.?
The FDA issued a warning letter citing regulatory violations related to their products or manufacturing practices.
Are Casmara Cosmetics, S.A. products safe to use?
Based on the FDA's findings, consumers should exercise caution. The company was found to have regulatory issues that may affect product safety.
What should I do if I've used Casmara Cosmetics, S.A. products?
If you have used products from Casmara Cosmetics, S.A. and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.

Source Document

This report is based on an official FDA warning letter. The original document is a public record.

View Original FDA Warning Letter
Medical Disclaimer: This report is an analysis of public FDA warning letters. It is not medical advice. If you have consumed these products and feel unwell, contact a healthcare professional immediately. You can report adverse events to the FDA MedWatch program.